:::Welcome to Macrogen:::
 
 
Home > Company > History
Established Macrogen Inc.
Founded a life resource bank for special disease models
Selected high-tech businesses by the Ministry of Science and Technology
    (to commercialize special disease models with xenotransplantation and
    application tech)
Certified as venture firm by the Small and Medium Business Administration
Certified as venture firm by the Small and Medium Business Administration
Established DNA Chip Service Center
Registered in KODAQ market among bio venture firm for the first time
Made strategic alliance on bioinformatics with HP Korea
Acquired first-ever animal patents on mice with immunodeficiency syndrome
    and diabetics in Korea (1st and 2nd patents)
Analyzed Zymmmonas mobillisi for the first time in the world
Opened a biomedical research institute and a bioinformatics institute
Granted Bioindustry Award 2000
Succeeded to clone mice for the first time in Korea
Made strategic alliance with Shanghai Gene Core (China) invested by
    Celera Genomics Corporation
Complete a draft on a gene map of Korean genome (Korean BAC Clone Map)
Register information on Zymmmonas mobillis on NCBI
Completed an advanced facility of SPF mice (in Gayang-dong Seoul)
Established a xenotransplantation-specialized company MGenbio Inc.
Entered into the joint research agreement to explore genes of Korean and
    Mongolian diseases with the Mongolian Ministry of Health
Entered into the supply agreement of DNA Chip and gene information
    analysis service with AS ONE (Japan)
Developed BAC DNA Chip
Entered into the supply agreement of knock-out mice with Transgenic (Japan)
Decoded information on genome of Corynebacterium ammoniagenes jointly
    with CJ Corp.
Entered into the agreement on joint research of bioinformatics with the
    Interdisciplinary Program in Bioinformatics Major in Seoul National University

Moved the head office (into World Merdian Venture Center
    in Gasan-dong Seoul)
Published "Birth of parthenogenetic mice that can develop to adulthood"
    to the Nature Publication
Made alliance on genetic diagnosis with Kreatech(from Netherlands)
Set Macrogen Young Scientist Award in the Korean Society for Biochemistry
    and Molecular Biology
Certified ISO9001 in whole sector of genetics
  Secured technical cooperation of DNA chip with Applied Biosystems (US)
MACROGEN, Corp., established in the US.
  Published "The genome sequence of the ethanologenic bacterium Zymomonasi
    mobilis ZM4” in the Nature publication
  Published “The genome project on Xanthomonas”in the Nucleic Acid
    Research (NAR) in collaboration with the Agricultural and Life Science
     Research Institute.
  Selected as the supervisory research center of the organizations
      for developing gene-based DNA chips for diseases.
  MGenbio first produced the cloned pigs for curing diabetes.
  DNA chips for research supplied to the KFDA.
    Yearly sales exceeded USD 10M.
    The MACROGEN USA began providing services for the local customers.
    First cloned pig born to facilitate the production of MGenbio anticancer
      substances by means of transformation.
  Received the 5th Annual Grand Prize for Digital Innovation from the Ministry of
      Industries and Resources.
Mr. Byonghwa Lee inaugurated as CEO
  Array CGH DNA chips for diagnosing chromosomal abnormalities (MACROGEN
      BAC Chips’) received the KFDA regulatory approval as an IVD test.
  A contract for exclusive rights to the DNA chips based on the
      semiconductor production method concluded with CombiMatrix in
      the US for the production and distribution in Korea
  Merged with Vector Core A Co., Ltd., a biotechnological firm
      specialized in developing novel gene delivery technologies
  A contract for the collaborative research on the commercialization
      of ethanol as fuel through bacterium Zymomonas concluded with Changhae
      Ethanol Co., Ltd.
  MG MED, a subsidiary company, merged with NeoGenetic Co., Ltd.,
      a firm specialized in genetic diagnosis.
  An agreement for the collaborative research on the development
      of clinical medicine and diagnostic chips concluded with
      Samsung Medical Center.
  Received an award for ‘MACROGEN BAC Chip H1400 (which diagnoses
      chromosomal abnormalities)’ at the Great Technological Contest,
      sponsored by the Technological Fair of the Health Industries in 2006.
Psoma Therapeutics, Inc., a subsidiary company specialized in the
      molecular diagnosis and molecular target discovery for drug
      development, was established.
  MACROGEN Japan Corp., established.
MACROGEN European Branch opened(Amstelveen, the Netherlands)